To OTC Journal Members:
 

Calypte Biomedical (OTC BB: CYPT)- The Hottest Stock on the Bulletin Board

I've gotten dozen of emails on Calypte Biomedical recently. Here are my comments on the hottest stock on the Bulletin Board today.

Calypte is the only company in the world with an FDA Approved test kit which uses urine instead of blood for HIV testing. The AIDS epidemic in third world countries represents an enormous market for their product, as it is far safer, more stable, and less expensive in the field.

As many of you know, I used to cover the company, but advised everyone to unload the stock last in March when I finally threw in the towel. As I recounted in the March 29th edition, I felt the company had outstanding technology but shareholders didn't have a chance until management stopped the endless flow of toxic financing, which created an excess supply of stock at a discount to the market no matter how low the market went.

In that edition I stated there were three possible events which could turn the stock around. The announcement of a non-toxic financing or partnership in the biotech industry was one of those events. Last week Calypte announced it had received a $10 million, non-toxic financing from an industry partner, and the stock has gone crazy ever since.

A look at a longer term chart easily leads one to the conclusion the stock was entitled to bounce back off ridiculously low levels. All the company had to do was quitting issuing shares at a discount to the market. As taken in context from when I first featured the stock in June of 2002, the stock has barely blipped up on the radar screen. During that time the company did a 30 for 1 reverse split. In order to regain the losses over the last 15 months, the stock would have to go to $13.

In the last quarterly earnings report, Calypte reported there were now 58 million shares issued and outstanding. With the additional financing, that number has undoubtedly grown into the 80 million share range. The stock is now trading at $1.15, suggesting the value of the company is rapidly approaching $100 million. Coincidentally, $100 million is almost exactly the amount that has been invested in the company.

The technology is awesome, but the market cap is a little rich when one considers the company only achieved $750,000 in sales last quarter. I would suggest this stock is a buy in the $.70 to $.85 range if it pulls back. Investors would be wise to keep an eye on the SEC filings. If you see any S-8 filings wherein the company is issuing free trading shares at a discount to the market to "consultants", you might watch for a return to the old pattern. If no such filings occur, this stock has virtually unlimited upside potential. In the $.75 to $.85 range I will probably buy some for my own account and look for $2 to $3.
 

CAM Commerce Systems (NASDAQ: CADA) - Quietly Sneaks to a New Multi Year High

Last week CAM Commerce Systems traded to a new multi year high of $6. I first reported on this company back in the February 28th edition, wherein I suggested you could buy a business enjoying $20 million in annual sales for next to nothing since the company had $3.50 per share in cash and no debt. At the time, shares were trading at $4.20. Last week's move to the $6 level yields a 43% gain in invested capital if you acted in the low $4's.

I like this stock for much higher levels. The stock is thinly traded, so it is not recommended for traders- it's a stealth stock for investors looking for value.

From a comparative analysis amongst industry competitors, the stock is trading at less than one times sales, as opposed to an industry average of close to two times sales (1.84x). At 1.84x sales for the trailing twelve months, the stock would be trading in the $10.00 to $11.00 range if it achieved the value the market awards to its competitors today.

The Company's balance sheet is equally compelling, with more than $11 million in cash, cash equivalents, and marketable securities, CAM has approximately $3.46 per share. On an earnings per share basis, CAM is poised for profitability, with little more than 3 million shares outstanding, every $300 thousand in profit is worth almost $.10 in EPS to the company.

CAM Commerce is in the middle of its seasonally busiest time. The company boast 10,000 retailers as customers, and many are beefing up their point of purchase systems for the Holiday season right now.

Furthermore, the company has evolved its business model and entered the credit card processing market wherein they get a transaction fee. This new market will bring a strong recurring revenue stream to the company during Holiday buying season and beyond.

The first six months got us from the low 4's to $6 and the first 40%. Look for the stock to move into the $8 to $12 range over the next six months. As of 8/21 Geoffrey Knapp, President and CEO, was still buying his company's stock in the open market.
 

Irvine Sensors (NASDAQ: IRSN) Delivers Improved Version of the Infrared Camera

Last Friday Irvine Sensors issued a press release revealing they had completed the development of their next generation infrared camera. This is one of the products Irvine Sensors is developing on the government's nickel, and has promise for use in homeland security applications and other military uses.

This little infrared camera, which isn't much bigger than the key to your front door, has multiple potential markets. Because it is so small and uses so little power, the military is experimenting with using the camera for night scopes on rifles. It reduces the weight of the weapon considerably.

The camera can also be placed at a remote location. It senses motion, and can transmit infrared images back to a monitoring station. It's ideal for remotely detecting intruders. The camera runs on a power source equivalent to a couple of AA batteries.

Irvine Sensors continues to prove they are the kings of small and powerful. They have developed the world's smallest computer, one of the world's smallest infrared cameras, and one of the world's most powerful stacked memory products.

Look for news of sales momentum for these products to put some life into the stock. 

Here is the complete text of the news release for your review:
 

Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketByte LLC has been paid a fee of 250,000 free trading shares of Calypte common stock by First Stage Capital for coverage of Calypte Biomed. On August 12, 2002, MarketByte LLC entered into an agreement directly with Calypte Biomed to continue coverage of the company through October 31, 2002. Calypte Biomed paid $25,000 cash as compensation, and an additional 300,000 shares of free trading stock were paid by a third party on behalf of the company. On November 1, 2002, MarketByte LLC and Calypte Biomed to agreed to renew the agreement to extend through January 31, 2003 in return for $25,000 in cash, and an additional 300,000 shares of free trading stock were paid by a third party.  MarketByte LLC has been paid a fee of $25,000 by Irvine Sensors for coverage through December 31, 2003. As part of the agreement, one of the prinicipals of MarketByte LLC has been awarded 75,000 options, with an exercise price of $1.35.

All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

The editor, members of the editor's family, and/or entities with which they are affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.